An engineering strategy to target activated EGFR with CAR T cells

cell.com/cell-reports-m…

⭐️Oligonucleotide therapeutics are emerging as a powerful platform for modulating gene expression across a range of diseases and applications.
Science Magazine scim.ag/6DR

The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers.
aacrjournals.org/cancerdiscover…
#btsm Cancer Discovery

Dans cette étude thérapie onco orale non utilisée peut être réattribuée sous condition de bonne conservation Economie (680-1591$/participant) et limitation des déchets (-68%) #Transition ADEME Laurent Greillier Yann Nguyen
jamanetwork.com/journals/jamao…

#openaccess ESMO - Eur. Oncology ESMO Open genomic profiling in the management of #patients w rare #cancers :
Rare cancer patients show favourable response to matched therapies, with a higher ORR in early treatment lines.

#PrecisionMedicine OncoAlert 🚨

esmoopen.com/article/S2059-…

🚨Our work on long-term outcomes to PD-1 monotherapy by increasing PD-L1 levels in #NSCLC is out in JTO & JTO CRR.
PD-L1 TPS ≥90% (vs 50-89%) is associated w/⬆️3-year PFS and OS rates and favorable genomic & immunophenotypic profiles. #LCSM IASLC
tinyurl.com/333zumjd
🧵1/10

Et bravo les PU Société de Pneumologie de Langue Française (SPLF)

'Les non-fumeurs sont souvent l'objet de tabagisme passif, il faut absolument qu'on progresse sur les lieux de santé sans tabac, sur l'interdiction de fumer dans les lieux publics' : le Pr Marie Wislez est l'invitée de Géraldine Mayr #FranceBleu et Anne Orenstein dans #BonjourDocteur

Local T cell neighbourhoods determine outcome in non-small cell lung cancer treatment with KRAS-G12C inhibitors.

Timely and relevant work from Megan Cole and Panayiotis Anastasiou from the @JulianDownwardlab, and Claudia Lee from the Swanton Lab.
doi.org/10.1101/2024.0…

NEW content online! Combinatorial strategies to target RAS-driven cancers dlvr.it/T5bYVg

Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab | Nature Reviews Clinical Oncology
✅ Herein, we argue that the most appropriate and rational sequence and/or combination of therapies remains a matter of discussion nature.com/articles/s4157…

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants

nature.com/articles/s4146…

Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers - European Journal of Cancer ejcancer.com/article/S0959-…

Just published in eBioMedicine – The Lancet Discovery Science!
Ever wondered why some heavy smokers never develop lung cancer, even in old age, while others do at a young age?
thelancet.com/journals/ebiom…

These clinically relevant phenotypes likely model extreme sensitivity and resistance to tobacco's

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

nature.com/articles/s4158…

Yes, CA-125 #KELIM is now calculated in > 101 countries in the world , representing >50% countries on the globe 🌎🌍🌏… with about 3600 /month on biomarker-kinetic.org for #ovarian cancer management … Arcagy-Gineco HCL - Hospices Civils de Lyon World Ovarian Cancer Day & WOCCoalition Ovarian Cancer Canada Salvovar

Cliniciens, chercheurs, directeurs, cadres, personnels de recherche et des soins, partenaires industriels, ne manquez pas la première journée sur la pneumologie aux HCL le 11 juin prochain à la médiathèque santé HCL - Hospices Civils de Lyon Sébastien Couraud 🫁🚭🌍 Université Lyon 1 Michael Duruisseaux

Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy nature.com/articles/s4159…

Practical guidance for sotorasib-related adverse events prevention and hepatotoxicity management - Michael Duruisseaux

oncodaily.com/47624.html

#oncodaily #oncology #cancer #LungCancerJournal #Sotorasib #AdverseEvents #Hepatotoxicity #MedicalGuidance #FrenchExpertise #MedicalResearch